Child Psychiatry and Human Development

, Volume 37, Issue 1, pp 55–64 | Cite as

Efficacy Profiles of Psychopharmacology: Divalproex Sodium in Conduct Disorder

  • Leena A. Khanzode
  • Kirti Saxena
  • Helena Kraemer
  • Kiki Chang
  • Hans Steiner
Original Paperr

Abstract

Little is known about how deeply medication treatment penetrates different levels of the mind/brain system. Psychopathology consists of relatively simple constructs (e.g., anger, irritability), or complex ones (e.g., responsibility). This study examines the efficacy of a specific compound, divalproex sodium (DVPX), on the various levels of psychopathology, utilizing a previous study in which 71 youth with conduct disorder were enrolled in a randomized controlled 7-week clinical trial. We examined weekly slopes of “emotional cognitions” of varying degrees of complexity obtained by Weinberger Adjustment Inventory (WAI), measuring more basic states, such as anger, depression, happiness and anxiety, and complex states, such as impulse control, consideration of others, responsibility and self-esteem. Intent-to-treat analyses showed significant associations between assignment to the active treatment and improvement in depression and impulse control. This is a rare clinical trial, which provides preliminary evidence for the different profiles of efficacy of medication treatment.

Keywords

Emotions Divalproex sodium Conduct disorder Clinical trial 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Chang K, Simeonova D (2004) Mood stabilizers: use in pediatric psychopharmacology. In: Steiner H (ed) Handbook of mental health interventions in children and adolescents. Jossey Bass, SFO CAGoogle Scholar
  2. 2.
    DiMascio A, Weissman MM, Prusoff BA (1979) Differential symptom reduction by drugs and psychotherapy in acute depression. Arch Gen Psychiatry 36(13):145–146Google Scholar
  3. 3.
    Rush AJ, Beck AT, Kovacs M (1982) Comparison of the effects of cognitive therapy pharmacotherapy on hopelessness and self-concept. Am J Psychiatry 139(7):862–866PubMedGoogle Scholar
  4. 4.
    Puig-Antich JP, Perel JM, Chambers WJ (1980) Imipramine treatment of prepubertal major depressive disorders: plasma levels and clinical response—preliminary report. Psychopharmacol Bull 16(1):25–27PubMedGoogle Scholar
  5. 5.
    Kosten JB, Frank E, Dan CJ (1991) Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. J Nerv Ment Dis 179:366–370PubMedCrossRefGoogle Scholar
  6. 6.
    FDA Warning: Possible Suicide, severe depression, anxiety, panic attacks in children and adolescents take any of the 10 popular antidepressants, especially at the beginning of the treatment or when the doses are increased or decreasedGoogle Scholar
  7. 7.
    Steiner H, Khanzode L, King M, Mordecai D (2004) Integrating treatment: a developmental perspective. In: Steiner H (ed) Handbook of mental health interventions in children and adolescents. Jossey Bass, SFO CAGoogle Scholar
  8. 8.
    Kandel E (1998) A new intellectual framework for psychiatry. Am J Psychiatry 155: 457–469PubMedGoogle Scholar
  9. 9.
    Gabbard GO, Kay J (2001) The fate of integrated treatment: whatever happened to the biopsychosocial psychiatrist?. Am J Psychiatry 158(12):1956–1963PubMedCrossRefGoogle Scholar
  10. 10.
    Searle J (2002) Consciousness and language. Cambridge University Press, NY, pp 18–35Google Scholar
  11. 11.
    Ekman P (1984) Expression and the nature of emotion. In: Scherer K, Ekman P (eds) Approaches to emotion. Erlbaum, Hillsdale NJGoogle Scholar
  12. 12.
    Ekman P (1993) Facial expression and emotion. Am Psychol 48(4):384–392 PubMedCrossRefGoogle Scholar
  13. 13.
    Steiner H, Petersen M, Saxena K (2003) Divalproex sodium for the treatment of severe conduct disorder: a randomized controlled clinical trial. J Clin Psychiatry 64:1183–1191PubMedCrossRefGoogle Scholar
  14. 14.
    Hollander E, Posner N, Cherkasy S (2002) Neropyschiatric aspects of aggression and impulse control disorders. In: Yudfshy SC, Hales RE (eds) American psychiatric press textbook of Neuropsychiatry. American Psychiatric press, Washington DC, pp 579–596Google Scholar
  15. 15.
    Weinberger DA (1997) Distress and self-restraint as measures of adjustment across the life span: confirmatory factor analysis in clinical and non-clinical samples. Psychol Assess 9(2):132–135CrossRefGoogle Scholar
  16. 16.
    Grissom RJ (1994) Probability of superior outcome of one treatment over another. J Appl Psychol 79(2):314–316CrossRefGoogle Scholar
  17. 17.
    Kraemer HC, Morgan GA, Leech NL, Gilner JA,Vaske JJ, Harmon RJ (2003) Measures of clinical significance. J Am Acad Child Adolesc Psychiatry 42(12):1524–1529PubMedCrossRefGoogle Scholar
  18. 18.
    Petty F, Kram M, Davis LL (1999) Valproate treatment of bipolar depression. Proceeding of 39th Annual NCDEU Meeting. Boca Raton FL: 70Google Scholar
  19. 19.
    Winsberg ME, DeGolia SG, Strong CM, Ketter TA (2001) Divalproex therapy in medication-naïve and mood stabilizer-naïve bipolar II depression. J Affect Disord 67:207–212PubMedCrossRefGoogle Scholar
  20. 20.
    Takebayashi M, Motohashi N, Saito H, Kagaya A, Yamawaki S (1995) Effect of acute treatment with sodium valproate on catecholamine and serotonin synthesis in mouse cerebral cortex. Neuropsychobiology 32:124–127PubMedCrossRefGoogle Scholar
  21. 21.
    Linnoila M, Virkkunen M, Scheinin M (1983) Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from non-impulsive violent behavior. Life Sci 33(26):2609–2614PubMedCrossRefGoogle Scholar
  22. 22.
    Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD (2002) Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania. Neuropsychopharmacology 26(4):530–536PubMedCrossRefGoogle Scholar
  23. 23.
    Donovan SJ, Stewart JW, Nunes EV (2000) Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design. Am J Psychiatry 157:818–820PubMedCrossRefGoogle Scholar
  24. 24.
    Hollander E, Allen A, Lopez RP (2001) A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry 62(3):199–203PubMedCrossRefGoogle Scholar
  25. 25.
    Hollander E, Tracy KA, Swann AC (2003) Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology 28(6):1186–1197PubMedGoogle Scholar
  26. 26.
    Hollander E, Swann A, Coccaro EF Divalproex sodium is superior to placebo for impulsive aggression in cluster B personality disorders. Abstract: 155th Annual Meeting of the American Psychiatric Association (APA); May 18–23, 2002; Philadelphia, PAGoogle Scholar
  27. 27.
    Hollander E, Evers M (2001) New developments in impulsivity. Lancet 358:949–950PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Leena A. Khanzode
    • 1
  • Kirti Saxena
    • 1
  • Helena Kraemer
    • 1
  • Kiki Chang
    • 1
  • Hans Steiner
    • 1
  1. 1.Division of Child Psychiatry and Child DevelopmentStanford University School of MedicineStanfordUSA

Personalised recommendations